Cancer is one of the most frequent diseases with a complex nature. The major challenge for cancer treatment is to deliver enough drugs to cure the cancer without having too high toxic side effects. The results of this project will increase the knowledge about the behavior of nanoparticles in the healthy and diseased body. Thus, the project will facilitate the development of nanoparticle-based products for imaging and therapy of cancer and will thereby contribute to an increased life standard for many patients.
Norway has high competence in various areas of nanoparticle-based drug delivery in cancer. This project was established to join forces of experts in the fields of nanoparticle development, cell biology, immunology, studies in animal tumor models and clinical studies, which is best achieved in a nationally coordinated research project. The experts involved have the necessary background to form an excellent platform for building competence in nanomedicine in Norway and to achieve the main goal of the project, to develop safe and efficient nanoparticle-based diagnosis and personalized therapy products for cancer.
SINTEF has set up a multidisciplinary team that will contribute to the project with the development and characterization of two types of nanoparticles, biodegradable inorganic hybrid nanoparticles (Department of Nano- and Hybrid Materials) and polymeric nanoparticles (Department of Polymer Particles and Surface Chemistry1). Research Scientist Yrr Mørch (firstname.lastname@example.org) will be contact person at SINTEF.
Project partners: Oslo University Hospital, SINTEF, NTNU, University of Tromsø and PCI Biotech AS. The project also includes collaboration with several other national groups and coworkers in Iceland, Denmark, Finland, Poland and Germany.
Project manager: Professor Kirsten Sandvig, Oslo University Hospital
Project budget: 30 MNOK
Project type: Nationally coordinated research project in NANO2021